ネットワーク分析を用いた異なる化学療法段階を有する乳がん患者における核心症状の特定:将来的な多中心長距離研究
Jiali He1, Dingxi Bai1, Huan Chen1
1School of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
Patient preference and adherence
|February 19, 2026
まとめ
この研究では,化学療法を受けている乳がん患者の核心症状を特定しました. 介入は,最初は睡眠障害とうつ病を標的とし,その後は食欲の減少と痛みを標的とし,疲労は後期の段階において中心となる.
科学分野:
- 腫瘍学 腫瘍学
- 症状科学 症状科学 症状科学
- ネットワーク分析 ネットワーク分析
背景:
- ネットワーク分析は,標的型乳がん治療戦略の主要な症状を特定するのに役立ちます.
- 乳がん患者の化学療法の異なる段階における症状ネットワークに関する研究は限られている.
研究 の 目的:
- 乳がん患者の異なる化学療法段階での介入のための主要な症状を特定する.
主な方法:
- 2022年11月から2023年10月までの間,467人の乳がん患者さんを対象に,多センター展望縦断調査が行われました.
- 化学療法を受けている乳がん患者の症状評価スケールでは,化学療法前 (T0),第1回 (T1),第3回 (T2),第6回 (T3) の治療後の4つの時間点での症状を測定しました.
- ネットワーク分析は,症状ネットワークとノード特性を調査した.
主要な成果:
- T0では,睡眠障害とうつ病が主な症状でした.
- T1では,食欲の低下と痛みが主な懸念事項として浮上しました.
- 疲労はT2とT3で最も中心的な症状として特定され,安定した症状ネットワークが全体的に観察されました.
結論:
- 介入を必要とする主な症状は,乳がん患者の化学療法段階によって異なります.
- ターゲットを絞った介入は,睡眠障害とうつ病 (T0),食欲低下と痛み (T1) に対処し,後の段階 (T2,T3) で疲労管理を優先すべきである.
関連する概念動画
Cancer Survival Analysis
788
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
788
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
657
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
657
